Conduct, Oversight, and Ethical Considerations of Clinical Trials in Companion Animals with Cancer: Report of a Workshop on Best Practice Recommendations

Journal of Veterinary Internal Medicine

Volumn 30, Issue 2, 2016, Pages 527-535

  Page, R ^a   Baneux, P ^b   Vail, D ^c   Duda, L ^d   Olson, P ^e   Anestidou, L ^f   Dybdal, N ^g   Golab, G ^h   Shelton, W ⁱ   Salgaller, M ^j   Hardy, C ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

^b Cornell University ^*  (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Animal Health and Welfare   (United States)

^f NATIONAL ACADEMY OF SCIENCES   (United States)

^g GENENTECH INC   (United States)

^h American Veterinary Medical Association   (United States)

ⁱ Virtual Beast Consulting   (United States)

^j The Conafay Group   (United States)

more..

Author keywords

Ethics; Oncology; Patient welfare; Treatments

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; BIOETHICS; CLINICAL TRIAL (TOPIC); ETHICS; METHODOLOGY; NEOPLASMS; PET ANIMAL; PRACTICE GUIDELINE; RESEARCH ETHICS; STANDARDS; VETERINARY;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOETHICS; CLINICAL TRIALS AS TOPIC; ETHICS, RESEARCH; NEOPLASMS; PETS; PRACTICE GUIDELINES AS TOPIC; RESEARCH DESIGN;

EID: 84961211649     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/jvim.13916     Document Type: Article

References (52)

1. Prier JE, Brodey RS. Canine Neoplasia: a prototype for human cancer study. Bull WHO 1963;29:331-344.
2. Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 2008;8:147-156.
3. Khanna C, London C, Vail D, et al. Guiding the optimal translation of new cancer treatments from canine to human cancer patients. Clin Cancer Res 2009;15:5671-5677.
4. Gordon I, Paoloni M, Mazcko C, Khanna C. The Comparative Oncology Trials Consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway. PLoS Med 2009;6:e1000161.
5. IOM (Institute of Medicine) Workshop: The Role of Clinical Studies for Pets with Naturally Occurring Tumors in Translational Cancer Research. Available at: https://iom.nationalacademies.org/Activities/Disease/NCPF/2015-JUN-08.aspx Accessed February 15, 2016.
6. Guidance for Industry - E6 Good Clinical Practice. US Dept of Health and Human Services, Food and Drug Administration 1996. Available at: http://www.fda.gov/downloads/Drugs/../Guidances/ucm073122.pdf. Accessed February 15, 2016.
7. American society of clinical oncology policy statement: oversight of clinical research. J Clin Oncol, 2003;21:2377-2386.
8. Report of the Clinical Trials Working Group of the National Cancer Advisory Board. Restructuring the National Cancer Clinical Trials Enterprise. June 2005. Available at: http://www.cancer.gov/about-nci/organization/ccct/about/ctwg-report.pdf. Accessed February 15, 2016.
9. Zon R, Meropol NJ, Catalano RB, Schilsky RL. American Society of Clinical Oncology statement on minimum standards and exemplary attributes of clinical trial sites. J Clin Oncol. 2008;26:2562-2567.
10. st Century: Second Workshop Summary. Washington, DC: The National Academies Press; 2013.
11. NRC [National Research Council]. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 2011. Available at: http://grants.nih.gov/grants/olaw/Guide-for-the-care-and-use-of laboratory-animals; Key Concepts. The Three Rs pp4-5.
12. Russell WMS, Burch RL. The Principles of Experimental Technique. London: Methuen and Co; 1959. [Reissued: 1992, Universities federation for Animal Welfare, Herts, UK]. Available at: http://altweb.jhsph.edu/pubs/books/humane_exp/het-toc.
13. Thamm DH, Vail DM. Veterinary oncology clinical trials: design and implementation. Vet J 2015;205:226-232 doi:10.1016/j.tvjI2014.12.013.
14. Marconato L, Buracco P, Aresu L. Perspectives on the design of clinical trials for targeted therapies and immunotherapy in veterinary oncology. Vet J 2015;205:238-243 doi: 10.1016/j.tvjl.2015.02.020.
15. Burton J, Khanna C. The role of clinical trials in veterinary oncology. Vet Clin North Am Small Anim Pract 2014;44:977-987.
16. Cook N, Hansen AR, Siu LL, Abdul RA. Early phase clinical trials to identify optimal dosing and safety. Mol Oncol 2015;9:997-1007.
17. Catenacci DV. Next-generation clinical trials: novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol 2015;9:967-996.
18. Dienstmann R1, Rodon J, Tabernero J. Biomarker-driven patient selection for early clinical trials. J Curr Opin Oncol 2013;25:305-312.
19. Takimoto CH. Phase 0 clinical trials in oncology: a paradigm shift for early drug development. Can Chemother Pharmacol 2009;63:703-709.
20. Abdoler E, Taylor H, Wendler D. The ethics of phase 0 trials. Clin Cancer Res 2008;14:3692-3597.
21. Daugherty CK, Ratain MJ, Emanuel EJ, et al. Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials. J Clin Oncol 2008;26:1371-1378.
22. Kossowsky J, Donado C, Berde CB. Immediate rescue designs in pediatric analgesic trials: a systematic review and meta-analysis. Anesthesiology 2014;122:150-171.
23. Sanderson C, Hardy J, Spruyt O, Currow DC. Placebo and nocebo effect in randomized controlled trials: the implications for research and practice. J Pain Symptom Manage 2013;46:722-730.
24. Nguyen SM, Thamm DH, Vail DM, London CA. Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document. Vet Comp Oncol 2013;13:176-183. doi: 10.1111/vco.12032.
25. Vail DM, Michels GM, Khanna C, et al. Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)-a veterinary cooperative oncology group (VCOG) consensus document. Vet Comp Oncol. 2009;8:28-37.
26. Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol 2011; Article first published online: 20 JUL 2011, doi: 10.1111/j.1476-5829.2011.00283.x.
27. Lynch S, Savary-Bataille K, Leeuw B, Argyle DJ. Development of a questionnaire assessing health-related quality-of-life in dogs and cats with cancer. Vet Comp Oncol. 2011;9:172-182.
28. Modified ECOG Perf Scores. Available at: http://ecog-acrin.org/resources/ecog-performance-status Accessed February 15, 2016.
29. Wilson MK, Collyar D, Chingos DT, et al. Outcomes and endpoints in cancer trials: bridging the divide. Lancet Oncol 2015;16:e43-e52.
30. Wilson MK, Karakasis K, Oza AM. Outcomes and endpoints in trials of cancer treatment: the past, present, and future. Lancet Oncol 2015;16:e32-e42.
31. Hosgood G, Scholl DT. The effect of different methods of accounting for observatons from euthanized animals in survival analysis. Prev Vet Med 2001;48:143-154.
32. Baneux PJR, Martin ME, Allen MJ, Hallman TM. Issues related to institutional animal care and use committees and clinical trials using privately owned animals. ILAR J 2014;55:200-209.
33. AVMA Policy - Establishment and Use of Veterinary Clinical Studies Committees. Available at: https://www.avma.org/KB/Policies/Pages/Establishment-and-Use-of-Veterinary-Clinical-Studies-Committees.aspx. 2015. Accessed February 15, 2016.
34. Amdur RJ, Bankert EA. Institutional Review Board Member Handbook, 3rd ed. Sudbury, MA: Jones and Bartlett Publishing; 2011.
35. FDA proposal: Document 2014-16492, Draft Informed Consent Information Sheet: Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors (79 Federal Register 41291).
36. FDA draft Guidance for consent process. Available at: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM405006.pdf Accessed February 15, 2016.
37. PRIM&R response to FDA proposal. Available at: http://www.primr.org/publicpolicy/. Accessed February 15, 2016.
38. IOM (Institute of Medicine). Contemporary Issues for Protecting Patients in Cancer Research: Workshop Summary. Washington, DC: The National Academies Press; 2014.
39. NCI Informed Consent Template. Available at: http://ctep.cancer.gov/protocolDevelopment/informed_consent.htm. Accessed February 15, 2016.
40. Lo B, Wolf LE, Berkley A. Conflict of Interest for Investigators in Clinical Trials. N Engl J Med 2000;343:1616-1620.
41. Financial Relationships and Interests in Research Involving Human Subjects: Guidance for Human Subject Protection 2004. Available at: http://www.hhs.gov/ohrp/policy/fguid.pdf. Accessed February 15, 2016.
42. Shekelle PG, Ruelaz A, Miake-Lye IM, et al. Maintaining Research Integrity: A Systematic Review of the Role of the Institutional Review Board in Managing Conflict of Interest, VA-ESP Project #05-226; 2012.
43. US Department of Health and Human Service Office of Research Integrity. Introduction to Responsible Conduct of Research. Available at: https://ori.hhs.gov/sites/default/files/rcrintro.pdf. Accessed February 15, 2016.
44. Joffe S, Cook EF, Cleary PD, et al. Quality of informed consent in cancer clinical trials: a cross sectional survey. Lancet 2001;358:1772-1777.
45. NCTN Audit Guidelines. Available at: http://ctep.cancer.gov/branches/ctmb/clinicalTrials/monitoring_coop_ccop_ctsu.htm. Accessed February 15, 2016.
46. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials. Open Med 2010;4:e60-e68 Epub 2010 Mar 24.
47. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 2010;63:e1-e37.
48. Clinical Trials.Gov. Available at: https://clinicaltrials.gov/. Accessed February 15, 2016.
49. Veterinary Cancer Society Clinical Trial Registry. Available at: http://www.vetcancersociety.org/members/clinical-trials/. Accessed February 15, 2016.
50. IOM (Institute of Medicine). Sharing Clinical Research Data: Workshop Summary. Washington, DC: The National Academies Press; 2013.
51. McGrath JC, McLachlan EM, Zeller R. Transparency in Research involving Animals: The Basel Declaration and the new principles for reporting research in BJP manuscripts. Br J Pharmacol 2015;172:2427-2432.
52. NIH Department of Bioethics. Available at: http://bioethics.nih.gov/courses/index.shtml. Accessed February 15, 2016.